Strong Market Performance and Recent Trends
Despite a slight decline of 0.75% in today’s trading session, Torrent Pharmaceuticals remains firmly above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day marks. The stock’s intraday volatility was notably high at 127.58%, underscoring active trading interest and dynamic price movements. Over the past week, the stock has gained 3.06%, outperforming the Sensex which declined by 0.81%. The one-month and three-month performances stand at 6.83% and 13.71% respectively, both significantly ahead of the Sensex’s negative returns for the same periods.
Longer-term performance further highlights Torrent Pharmaceuticals’ strength. The stock has delivered a remarkable 28.46% return over the last year, compared to the Sensex’s 7.62%. Year-to-date, it has gained 5.68% while the benchmark index has fallen by 2.67%. Over three and five years, the stock has surged by 156.52% and 198.24% respectively, vastly outperforming the Sensex’s 36.83% and 66.59% gains. The ten-year return is particularly striking at 519.68%, more than double the Sensex’s 244.73% rise.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Strength and Operational Metrics
Torrent Pharmaceuticals’ financial health is underscored by a high Return on Capital Employed (ROCE) of 24.08%, reflecting efficient management of capital resources. The company’s ability to service debt is strong, with a low Debt to EBITDA ratio of 1.01 times, indicating prudent leverage levels. The operating profit to interest ratio for the latest quarter stands at an impressive 22.56 times, highlighting substantial earnings coverage over interest obligations.
Profit after tax (PAT) for the quarter reached a peak of Rs.600.71 crores, while the half-year ROCE improved to 27.85%. Torrent Pharmaceuticals has reported positive results for nine consecutive quarters, demonstrating consistent profitability and operational resilience. Institutional investors hold a significant 25.28% stake in the company, signalling confidence from entities with extensive analytical capabilities.
The company’s Mojo Score is 71.0, with a current Mojo Grade of Buy, upgraded from Hold on 23 December 2025. Torrent Pharmaceuticals is ranked among the top 1% of over 4,000 stocks rated by MarketsMojo, reflecting its superior quality and market standing.
Valuation and Growth Considerations
While Torrent Pharmaceuticals has exhibited strong returns and operational metrics, certain valuation aspects warrant attention. The company’s ROCE of 30.4 corresponds with a relatively high Enterprise Value to Capital Employed ratio of 13.4, indicating a premium valuation. However, the stock currently trades at a discount relative to its peers’ historical averages.
Net sales have grown at an annualised rate of 8.93% over the past five years, a moderate pace compared to the stock’s price appreciation. Profit growth over the last year has been robust at 24.6%, yet the Price/Earnings to Growth (PEG) ratio stands at 2.6, suggesting that earnings growth is priced in at a premium level.
Get the full story on Torrent Pharmaceuticals Ltd.! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology large-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Torrent Pharmaceuticals has consistently outperformed the broader BSE500 index in each of the last three annual periods. The company’s sustained growth and strong financial metrics place it among the leading players in its industry segment. Its market capitalisation grade is rated 1, reflecting its status as a large-cap entity with significant market presence.
Despite the stock’s recent three-day rally ending with a slight pullback today, the overall trend remains positive. The stock’s ability to maintain levels above all major moving averages supports the view of a sustained upward trajectory over the medium to long term.
Summary of Key Metrics
• All-time high stock price: Rs.4124.95
• One-year return: 28.46% vs Sensex 7.62%
• Three-year return: 156.52% vs Sensex 36.83%
• Five-year return: 198.24% vs Sensex 66.59%
• Ten-year return: 519.68% vs Sensex 244.73%
• ROCE: 24.08% (quarterly), 27.85% (half-year)
• Debt to EBITDA ratio: 1.01 times
• Operating profit to interest ratio: 22.56 times
• PAT (quarterly): Rs.600.71 crores
• Institutional holdings: 25.28%
• Mojo Score: 71.0 (Buy, upgraded from Hold on 23 Dec 2025)
Conclusion
Torrent Pharmaceuticals Ltd.’s ascent to a new all-time high of Rs.4124.95 is a testament to its consistent financial performance, strong management efficiency, and sustained market confidence. The company’s track record of positive quarterly results, robust profitability ratios, and significant institutional backing underpin this milestone. While valuation metrics suggest a premium, the stock’s long-term returns and sector leadership remain noteworthy.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
